Glucotrace (Fludeoxyglucose (18f))

Glucotrace is employed in several PET imaging applications to evaluate metabolic activity in the body. It assists physicians in diagnosing and managing a range of conditions.

• Oncologic PET imaging for tumor detection, staging, and treatment response assessment.
• Cardiac PET imaging to evaluate myocardial viability and perfusion.
• Neurologic PET imaging for brain metabolism studies, including dementia and epilepsy evaluation.
• Research studies investigating glucose metabolism in various disease models.
• Companion diagnostic use when paired with targeted therapies.

Adverse reactions to Glucotrace are generally infrequent but may occur following intravenous administration. Most events are mild and transient.

Common

• Mild injection site discomfort or erythema.
• Transient nausea or vomiting.
• Temporary headache.
• Low-grade fever.
• Mild allergic skin reactions such as urticaria.

Serious

• Anaphylactic or severe hypersensitivity reactions.
• Significant hypotension or cardiovascular collapse.
• Acute renal impairment in susceptible patients.
• Severe radiation‑related tissue injury (rare with standard dosing).

Glucotrace should be used with careful consideration of patient‑specific factors and procedural protocols. Key safety points include:

• Verify patient identity and confirm indication before administration.
• Assess renal function, especially in patients with known impairment.
• Use appropriate radiation protection measures for staff and surrounding individuals.
• Pregnant or breastfeeding patients should be evaluated for risk versus benefit, as fetal exposure is unknown.
• Ensure proper handling and disposal of radioactive waste according to local regulations.
• Monitor patients for immediate adverse reactions during and after injection.

Glucotrace may interact with other substances that affect glucose metabolism or radiation exposure. Consider the following:

Avoid

• Concurrent administration of high‑dose glucose or dextrose solutions that could compete for cellular uptake.
• Use of other radiopharmaceuticals within 24 hours that may increase cumulative radiation dose.

Use with caution

• Medications that alter blood glucose levels (e.g., insulin, oral hypoglycemics) as they may affect tracer distribution.
• Contrast agents used in CT imaging performed immediately before or after PET, which could affect image interpretation.
• Drugs that influence renal clearance, potentially modifying tracer elimination.